Literature DB >> 12815113

The role of parenteral lipids in supporting gluconeogenesis in very premature infants.

Agneta L Sunehag1.   

Abstract

We have previously demonstrated that very premature infants receiving glucose at 17 micromol/kg min plus appropriate supply of parenteral lipids (Intralipid) and amino acids (TrophAmine) maintained normoglycemia by glucose produced primarily via gluconeogenesis. The present study addressed the individual roles of parenteral lipids and amino acids in supporting gluconeogenesis. Fourteen premature infants (993 +/- 36 g 27 +/- 1 wk) (mean +/- SE) were studied for 8 h on d 5 +/- 1 of life. All infants were receiving standard TPN prior to the study. At start of study, the glucose infusion rate was decreased to approximately 17 micromol/kg min and either Intralipid (g + AA; n = 8) or TrophAmine (g + IL; n = 6) was discontinued. Data from 14 previously studied infants receiving glucose (approximately 17 micromol/kg min) + TrophAmine + Intralipid (g + AA + IL) are included for comparison. Gluconeogenesis was measured by [U-13 C]glucose, (g + AA) and (8 infants of the g + AA + IL group) or [2-13C]glycerol, (g + IL) and (6 infants of the g + AA + IL group). Infants studied by the same method were compared. Withdrawal of Intralipid resulted in decreased gluconeogenesis, 6.3 +/- 0.9 (g +AA) vs. 8.4 +/- 0.7 micromol/kg min (g + AA + IL) (p = 0.03). Withdrawal of TrophAmine affected neither total gluconeogenesis, 7.5 +/- 0.8 vs. 7.9 +/- 0.9 micromol/kg min nor gluconeogenesis from glycerol, 4.4 +/- 0.6 vs. 4.9 +/- 0.7 micromol/kg min (g+ IL and g + AA + IL groups, respectively). In conclusion, in parenterally fed very premature infants, lipids play a primary role in supporting gluconeogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815113     DOI: 10.1203/01.PDR.0000081298.06751.76

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Gluconeogenesis is not regulated by either glucose or insulin in extremely low birth weight infants receiving total parenteral nutrition.

Authors:  Shaji K Chacko; Jorge Ordonez; Pieter J J Sauer; Agneta L Sunehag
Journal:  J Pediatr       Date:  2011-02-15       Impact factor: 4.406

Review 2.  On the problem of patient-specific endogenous glucose production in neonates on stochastic targeted glycemic control.

Authors:  Jennifer L Dickson; James N Hewett; Cameron A Gunn; Adrienne Lynn; Geoffrey M Shaw; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2013-07-01

Review 3.  Strategies for feeding the preterm infant.

Authors:  William W Hay
Journal:  Neonatology       Date:  2008-10-02       Impact factor: 4.035

Review 4.  Parenteral lipid emulsions in the preterm infant: current issues and controversies.

Authors:  Lauren C Frazer; Camilia R Martin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2021-01-29       Impact factor: 5.747

Review 5.  Intravenous lipids for preterm infants: a review.

Authors:  Ghassan Sa Salama; Mahmmoud Af Kaabneh; Mai N Almasaeed; Mohammad Ia Alquran
Journal:  Clin Med Insights Pediatr       Date:  2015-02-09

6.  Indications and complications of inpatient parenteral nutrition prescribed to children in a large tertiary referral hospital.

Authors:  C Mantegazza; N Landy; G V Zuccotti; J Köglmeier
Journal:  Ital J Pediatr       Date:  2018-06-08       Impact factor: 2.638

Review 7.  Neonatology/Paediatrics - Guidelines on Parenteral Nutrition, Chapter 13.

Authors:  C Fusch; K Bauer; H J Böhles; F Jochum; B Koletzko; M Krawinkel; K Krohn; S Mühlebach
Journal:  Ger Med Sci       Date:  2009-11-18

8.  Administration of an Intravenous Fat Emulsion Enriched with Medium-Chain Triglyceride/ω-3 Fatty Acids is Beneficial Towards Anti-Inflammatory Related Fatty Acid Profile in Preterm Neonates: A Randomized, Double-Blind Clinical Trial.

Authors:  Panos Papandreou; Aristea Gioxari; Dimitrios Ntountaniotis; Olga-Natalia Korda; Maria Skouroliakou; Tania Siahanidou
Journal:  Nutrients       Date:  2020-11-16       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.